Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 6 , ISSUE 1 ( January-June, 2016 ) > List of Articles

MINI REVIEW

Past, Present, and Future of Viral Hepatitis C in Japan

Hiroshi Yatsuhashi

Citation Information : Yatsuhashi H. Past, Present, and Future of Viral Hepatitis C in Japan. Euroasian J Hepatogastroenterol 2016; 6 (1):49-51.

DOI: 10.5005/jp-journals-10018-1166

License: CC BY-NC 4.0

Published Online: 01-01-2016


Abstract

Of all the industrialized countries of the world, Japan has the highest rate of hepatitis C. It also has 1 of the oldest and most varied histories of hepatitis C in the world among the industrialized modern nations. Hepatitis C and its complications are the leading cause of liver cancer in Japan. Japan has the highest rate of liver cancer among the industrialized countries. From 2004 to 2014, PegIFN/RBV treatment was the mainstream of hepatitis C treatment. In 2014, the first interferon-free therapy was approved in Japan. Subsequently, other interferon-free therapies have been approved. Hepatitis C virus disinfection in hepatitis C patients in Japan has become possible with a probability of 96% or more.


PDF Share
  1. Franciscus A. HCV Around the World: Japan. HCV Advocate 2015. Available from: http://www.hcvadvocate.org/ 2. Blaxell V. Yellow blood: hepatitis C and the modernist settlement in Japan. Asia-Pacific J 2014 May 5;12(18 No 1):1-18
  2. Molecular evolutionary analyses implicate injection treatment for schistosomiasis in the initial hepatitis C epidemics in Japan. J Hepatolol 2005 Jan;42(1):47-53
  3. Methamphetamine use in Japan after the Second World War: transformation of narratives. Contemp Drug Probl 2008 Dec;35(4):717-746
  4. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014 Jun;59(6):2083-2089
  5. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat 2014 Nov;21(11):762-768
  6. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015 Jun;15(6):645-653.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.